Validation of the Spanish Version of the Clinically Useful Depression Outcome Scale (CUDOS) Scale

Sponsor
AstraZeneca (Industry)
Overall Status
Completed
CT.gov ID
NCT01360307
Collaborator
(none)
330
17
5
19.4
3.9

Study Details

Study Description

Brief Summary

The Clinically Useful Depression Outcome Scale (CUDOS) is a brief, self-administered instrument that not only evaluates depressive symptoms but also both functioning and quality of life. The assessment of patients´ perspective may provide valuable information that could be lost if relaying only on clinician evaluation. The purpose of this study is to achieve a psychometric validation into Spanish of the CUDOS scale in patients with major depression disorder in a primary care setting.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    330 participants
    Time Perspective:
    Cross-Sectional
    Official Title:
    Psychometric Validation of the Spanish Version of the CUDOS Scale (Clinically Useful Depression Outcome Scale) in Major Depressive Disorder
    Study Start Date :
    Jun 1, 2011
    Actual Primary Completion Date :
    Nov 1, 2011
    Actual Study Completion Date :
    Nov 1, 2011

    Arms and Interventions

    Arm Intervention/Treatment
    Major Depressive Disorder Patients

    Outcome Measures

    Primary Outcome Measures

    1. Clinically Useful Depression Outcome Scale [up to 12 weeks after a diagnoses of a major depressive disorder]

      To analyze feasibility and reliability (internal consistency - Cronbach´s alpha) of the Spanish version of the scale

    Secondary Outcome Measures

    1. Hamilton Depression Rating Scale [up to 12 weeks after a diagnoses of a major depressive disorder]

      To analyze convergent validity of the Spanish version of the CUDOS scale

    2. SF 36 [up to 12 weeks after a diagnoses of a major depressive disorder]

      To analyze correlation in quality of life -item 18 of the CUDOS scale

    3. Patient Global Impression Scale [up to 12 weeks after a diagnoses of a major depressive disorder]

      To analyze criterion validity of the Spanish version of the CUDOS scale

    4. Social Occupational Functioning Scale [up to 12 weeks after a diagnoses of a major depressive disorder]

      To analyze correlation in functioning -item 17 of the CUDOS scale

    5. Clinically Global Impression Scale [up to 12 weeks after a diagnoses of a major depressive disorder]

      To analyze criterion validity of the Spanish version of the CUDOS scale

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Major depression disorder diagnosis according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria in the last 3 months

    • Major depression disorder diagnosis according to Prime-MD criteria in the last 3 months

    Exclusion Criteria:
    • Be unable to understand and comply with the study requirements as judged by the investigator

    • Participation in another trial prior to enrolment into this study

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Research Site A Coruña Spain
    2 Research Site Barcelona Spain
    3 Research Site Cadiz Spain
    4 Research Site Cordoba Spain
    5 Research Site El Vendrell Spain
    6 Research Site Granada Spain
    7 Research Site Huelva Spain
    8 Research Site Lugo Spain
    9 Research Site Madrid Spain
    10 Research Site Majadahonda Spain
    11 Research Site Malaga Spain
    12 Research Site Nigran Spain
    13 Research Site Palma Mallorca Spain
    14 Research Site Salamanca Spain
    15 Research Site Terrasa Spain
    16 Research Site Tudela Spain
    17 Research Site Vigo Spain

    Sponsors and Collaborators

    • AstraZeneca

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    AstraZeneca
    ClinicalTrials.gov Identifier:
    NCT01360307
    Other Study ID Numbers:
    • NIS-NES-XXX-2011/1
    First Posted:
    May 25, 2011
    Last Update Posted:
    Dec 6, 2011
    Last Verified:
    Dec 1, 2011
    Keywords provided by AstraZeneca
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 6, 2011